Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Constant pattern of relapse in primary central nervous lymphoma patients treated with high-dose methotrexate combinations. A Finnish retrospective study.
Harjama L, Kuitunen H, Turpeenniemi-Hujanen T, Haapasaari KM, Leppä S, Mannisto S, Karjalainen-Lindsberg ML, Lehtinen T, Eray M, Vornanen M, Haapasalo H, Soini Y, Jantunen E, Nousiainen T, Vasala K, Kuittinen O. Harjama L, et al. Among authors: vasala k. Acta Oncol. 2015 Jun;54(6):939-43. doi: 10.3109/0284186X.2014.990110. Epub 2015 Mar 11. Acta Oncol. 2015. PMID: 25761092
Blood graft cellular composition and posttransplant recovery in non-Hodgkin's lymphoma patients mobilized with or without plerixafor: a prospective comparison.
Valtola J, Varmavuo V, Ropponen A, Nihtinen A, Partanen A, Vasala K, Lehtonen P, Penttilä K, Pyörälä M, Kuittinen T, Silvennoinen R, Nousiainen T, Pelkonen J, Mäntymaa P, Jantunen E. Valtola J, et al. Among authors: vasala k. Transfusion. 2015 Oct;55(10):2358-68. doi: 10.1111/trf.13170. Epub 2015 May 28. Transfusion. 2015. PMID: 26018461 Clinical Trial.
Promising treatment results with blood brain barrier disruption (BBBD) based immunochemotherapy combined with autologous stem cell transplantation (ASCT) in patients with primary central nervous system lymphoma (PCNSL).
Kuitunen H, Tokola S, Siniluoto T, Isokangas M, Sonkajärvi E, Alahuhta S, Turpeenniemi-Hujanen T, Jantunen E, Nousiainen T, Vasala K, Kuittinen O. Kuitunen H, et al. Among authors: vasala k. J Neurooncol. 2017 Jan;131(2):293-300. doi: 10.1007/s11060-016-2293-8. Epub 2016 Oct 17. J Neurooncol. 2017. PMID: 27752883
Integrin alpha 10, CD44, PTEN, cadherin-11 and lactoferrin expressions are potential biomarkers for selecting patients in need of central nervous system prophylaxis in diffuse large B-cell lymphoma.
Lemma SA, Kuusisto M, Haapasaari KM, Sormunen R, Lehtinen T, Klaavuniemi T, Eray M, Jantunen E, Soini Y, Vasala K, Böhm J, Salokorpi N, Koivunen P, Karihtala P, Vuoristo J, Turpeenniemi-Hujanen T, Kuittinen O. Lemma SA, et al. Among authors: vasala k. Carcinogenesis. 2017 Aug 1;38(8):812-820. doi: 10.1093/carcin/bgx061. Carcinogenesis. 2017. PMID: 28854563 Free PMC article.
Mutation of TP53, translocation analysis and immunohistochemical expression of MYC, BCL-2 and BCL-6 in patients with DLBCL treated with R-CHOP.
Peroja P, Pedersen M, Mantere T, Nørgaard P, Peltonen J, Haapasaari KM, Böhm J, Jantunen E, Turpeenniemi-Hujanen T, Rapakko K, Karihtala P, Soini Y, Vasala K, Kuittinen O. Peroja P, et al. Among authors: vasala k. Sci Rep. 2018 Oct 4;8(1):14814. doi: 10.1038/s41598-018-33230-3. Sci Rep. 2018. PMID: 30287880 Free PMC article.
Comparison of filgrastim, pegfilgrastim, and lipegfilgrastim added to chemotherapy for mobilization of CD34+ cells in non-Hodgkin lymphoma patients.
Partanen A, Valtola J, Ropponen A, Kuitunen H, Kuittinen O, Vasala K, Ågren L, Penttilä K, Keskinen L, Pyörälä M, Nousiainen T, Selander T, Mäntymaa P, Pelkonen J, Varmavuo V, Jantunen E. Partanen A, et al. Among authors: vasala k. Transfusion. 2019 Jan;59(1):325-334. doi: 10.1111/trf.14993. Epub 2018 Nov 19. Transfusion. 2019. PMID: 30450652
30 results